Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This appears to be a **nonstandard compounded combination product description** referring to a mixture containing the corticosteroids triamcinolone acetonide and dexamethasone sodium plus the local anesthetic bupivacaine hydrochloride, with isopropyl alcohol as an antiseptic/excipient rather than a therapeutic active ingredient. Mechanistically, triamcinolone acetonide and dexamethasone act as glucocorticoid receptor agonists that suppress inflammatory gene transcription, while bupivacaine blocks voltage-gated sodium channels to provide local anesthesia. However, the exact four-component combination named here could not be verified as a distinct marketed or clinical-stage drug product from the supplied evidence; the provided indication text instead matches labeling for injectable corticosteroid products and related procedural kits rather than a clearly identified unique drug asset.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on triamcinolone acetonide + bupivacaine hydrochloride + isopropyl alcohol + dexamethasone sodium.